Please assess the completion status of the following clinical trial:

Trial Title: Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients, male or female, greater than 18 years with a clinical diagnosis of systemic sclerosis fulfilling the criteria of the American College of Rheumatology (formerly the American Rheumatism Association) classification criteria for systemic sclerosis, and diffuse cutaneous involvement based on the criteria of LeRoy et al~* Onset of skin sclerosis less than or equal to 48 months before study entry.~* Extent of skin sclerosis involving the trunk and/or arms and legs proximally to the elbows and/or knees.~* Present regimen consisting of one of the following: cellcept, D-penicillamine, methotrexate or cyclophosphamide.~* Previous history of using an alternative antifibrotic agent prior to present regimen will be permitted.~* Total antifibrotic treatment regimen duration should be less than or equal to 48 months.~Exclusion Criteria:~* Systemic sclerosis with skin involvement confined to face or acral regions of the body.~* Chemically induced scleroderma.~* Diffuse fasciitis.~* Mixed connective tissue disease and overlap syndromes.~* Pregnancy or nursing.~* Use of non-reliable method of contraception.~* Major surgery in the past month.~* Inability or unwillingness to provide written informed consent.~* Inability or unwillingness to comply with the requirements of the protocol as determined by the investigator.~* Known hypersensitivity or contraindication to ambrisentan

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- open label: medication Ambrisentan (Type: OTHER): Open label study of Ambrisentan.~Ambrisentan will begin at 5mg daily for the first month.~Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week. Subjects will continue their present dose and schedule of disease modifying/antifibrotic medication for the duration of the study.~\*\* Dose escalation was attempted however none of the patients were able to increase. Therefore all subjects remained on 5 mg daily throughout the study. 12 patients on mycophenolate mofetil, 2 on mycophenolic acid and one on methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).